Cerebrolysin
Aliases: Cerebrolysin (EVER Pharma)
Last verified: 2026-09-23
The short version
A mixture of low-molecular-weight peptides and amino acids from porcine brain — approved in 40+ countries for dementia, stroke and brain injury. A "natural" neurotrophic complex.
Identity & type
- Molecular type
- peptide
- Origin
- A mixture of low-molecular-weight peptides and amino acids from porcine brain — approved in 40+ countries for dementia, stroke and brain injury.
Mechanism of action
Contains BDNF/NGF/CNTF-like fragments; reduces apoptosis, improves synaptic plasticity and neuronal metabolism.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 10–30 mL IV/IM daily, 10–20 days per course.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
10–30 mL IV/IM daily, 10–20 days per course. The community (especially Eastern Europe) reports improved clarity, memory and recovery from fatigue; courses of 10–20 injections. Clinically known in dementia/brain injury.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
The community (especially Eastern Europe) reports improved clarity, memory and recovery from fatigue; courses of 10–20 injections. Clinically known in dementia/brain injury.
Protocol — official vs community
Official / label
Approved in 40+ countries (not FDA/EMA) for stroke, vascular dementia, traumatic brain injury and age-related cognitive decline: 10–30 mL IV/IM once daily.
- 01Treatment usually initiated at 10 mL daily and increased toward 30 mL per indication and tolerability
Duration: 10–20 days per course; courses may repeat after a drug-free interval of weeks to months per label.
Porcine-brain-derived peptide mixture; meta-analyses show modest benefit in vascular dementia and post-stroke recovery. Allergic reactions (rash, rarely anaphylaxis) are the main safety concern.
Community (anecdotal)
Imported gray-market ampoules used exactly per the label pattern: 10–30 mL IV or IM daily.
- Cycle:
- 10–20 day courses, repeated 2–4× per year.
- Break:
- Several weeks to months between courses.
The nootropic community treats it as an injectable 'neurotrophic' course despite the absence of FDA/EMA approval; the course structure, at least, is the legitimate one.
Human evidence
Trials and meta-analyses in vascular dementia and stroke (modest-to-moderate benefit); not FDA/EMA approved.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Dizziness, headache, rare allergic reactions.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use